VSIG1
V-set and immunoglobulin domain-containing protein 1
Also known as: GPA34, MGC44287, VSIG1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86XK7
- Gene
- VSIG1
- Ensembl
- ENSG00000101842
- Chromosome
- X
- Canonical length
- 387 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Vesicles,Cytosol
OverviewNCBI Gene
This gene encodes a member of the junctional adhesion molecule (JAM) family. The encoded protein contains multiple glycosylation sites at the N-terminal region, and multiple phosphorylation sites and glutamic acid/proline (EP) repeats at the C-terminal region. The gene is expressed in normal stomach and testis, as well as in gastric, esophageal and ovarian cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009]
Canonical amino-acid sequenceUniProt
387 residues, UniProt reviewed canonical sequence.
>Q86XK7|VSIG1
1 MVFAFWKVFL ILSCLAGQVS VVQVTIPDGF VNVTVGSNVT LICIYTTTVA SREQLSIQWS
61 FFHKKEMEPI SIYFSQGGQA VAIGQFKDRI TGSNDPGNAS ITISHMQPAD SGIYICDVNN
121 PPDFLGQNQG ILNVSVLVKP SKPLCSVQGR PETGHTISLS CLSALGTPSP VYYWHKLEGR
181 DIVPVKENFN PTTGILVIGN LTNFEQGYYQ CTAINRLGNS SCEIDLTSSH PEVGIIVGAL
241 IGSLVGAAII ISVVCFARNK AKAKAKERNS KTIAELEPMT KINPRGESEA MPREDATQLE
301 VTLPSSIHET GPDTIQEPDY EPKPTQEPAP EPAPGSEPMA VPDLDIELEL EPETQSELEP
361 EPEPEPESEP GVVVEPLSED EKGVVKALocalizationUniProt · AlphaFold · HPA
Whether an antibody against VSIG1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 183 nTPM
Expression across tissuesHPA
Tissue
- stomach: 183 nTPM
- testis: 45 nTPM
- urinary bladder: 8.3 nTPM
- gallbladder: 7.8 nTPM
- pituitary gland: 2.4 nTPM
- lymph node: 1.7 nTPM
Single-cell type
- foveolar cells: 669 nCPM
- mucous neck cells: 177 nCPM
- sertoli cells: 107 nCPM
- gastric chief cells: 106 nCPM
- parietal cells: 69 nCPM
- pituitary stem cells: 43 nCPM
Immune cell
- T-reg: 13 nTPM
- naive CD4 T-cell: 12 nTPM
- memory CD4 T-cell: 8.1 nTPM
- naive CD8 T-cell: 5.8 nTPM
- MAIT T-cell: 3.8 nTPM
- memory CD8 T-cell: 3.5 nTPM
Brain region
- basal ganglia: 1.7 nTPM
- cerebral cortex: 1.6 nTPM
- choroid plexus: 1.4 nTPM
- hypothalamus: 1.4 nTPM
- amygdala: 1.2 nTPM
- cerebellum: 1.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.98
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.46
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VSIG1 as an antibody target. Whether an autoantibody or antibody against VSIG1 could matter depends on whether native VSIG1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VSIG1 is annotated at the cell surface, where native VSIG1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label VSIG1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...